September 2026

WHAT THE INVEST-HD TRIAL COULD MEAN FOR HUNTINGTON’S DISEASE CARE

Huntington’s disease (HD) research is entering a pivotal period, with multiple investigational therapies advancing through late-stage clinical development. Danny Bega, MD, director of Northwestern Medicine Huntington's Disease Center, discusses the phase 3 INVEST-HD trial evaluating votoplam, an oral therapy designed to reduce production of mutant huntingtin protein.

Dr. Bega explains the trial's design, why scientists are focusing on patients with early symptomatic disease, and what recent advances could mean for the future of HD care. He also shares insights on the broader HD research landscape, including gene therapies, antisense oligonucleotides and other disease-modifying approaches currently under investigation.
Danny Bega, MD, Associate Professor of Movement Disorders at Northwestern Medicine

Refer a Patient

Northwestern Medicine welcomes the opportunity to partner with you in caring for your patients. ​

You May Also Like